IN2014DN10629A - - Google Patents
Download PDFInfo
- Publication number
- IN2014DN10629A IN2014DN10629A IN10629DEN2014A IN2014DN10629A IN 2014DN10629 A IN2014DN10629 A IN 2014DN10629A IN 10629DEN2014 A IN10629DEN2014 A IN 10629DEN2014A IN 2014DN10629 A IN2014DN10629 A IN 2014DN10629A
- Authority
- IN
- India
- Prior art keywords
- epitopes
- tumour
- cancer
- treatment
- relates
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 201000011510 cancer Diseases 0.000 abstract 2
- 239000004475 Arginine Substances 0.000 abstract 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 abstract 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 abstract 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 abstract 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 abstract 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 abstract 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 abstract 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 235000009582 asparagine Nutrition 0.000 abstract 1
- 229960001230 asparagine Drugs 0.000 abstract 1
- 230000006329 citrullination Effects 0.000 abstract 1
- 235000013477 citrulline Nutrition 0.000 abstract 1
- 229960002173 citrulline Drugs 0.000 abstract 1
- 230000009615 deamination Effects 0.000 abstract 1
- 238000006481 deamination reaction Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 abstract 1
- 230000008105 immune reaction Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 238000006396 nitration reaction Methods 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001162—Kinases, e.g. Raf or Src
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001176—Heat shock proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001188—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
- G01N2440/18—Post-translational modifications [PTMs] in chemical analysis of biological material citrullination
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Developmental Biology & Embryology (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1214007.5A GB201214007D0 (en) | 2012-08-07 | 2012-08-07 | Anti-tumour immune responses to modified self-epitopes |
| PCT/GB2013/052109 WO2014023957A2 (en) | 2012-08-07 | 2013-08-07 | Anti-tumour response to modified self-epitopes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN10629A true IN2014DN10629A (es) | 2015-09-11 |
Family
ID=46934958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN10629DEN2014 IN2014DN10629A (es) | 2012-08-07 | 2013-08-07 |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US10233220B2 (es) |
| EP (3) | EP3301447B1 (es) |
| JP (2) | JP6490581B2 (es) |
| KR (1) | KR102203096B1 (es) |
| CN (2) | CN104823054B (es) |
| AU (1) | AU2013301341B2 (es) |
| BR (1) | BR112015002574A8 (es) |
| CA (1) | CA2874515A1 (es) |
| DK (3) | DK2883054T3 (es) |
| ES (3) | ES2843777T3 (es) |
| GB (1) | GB201214007D0 (es) |
| HK (1) | HK1206427A1 (es) |
| IN (1) | IN2014DN10629A (es) |
| PL (2) | PL3301447T3 (es) |
| PT (3) | PT3301447T (es) |
| SG (2) | SG11201407804RA (es) |
| WO (1) | WO2014023957A2 (es) |
| ZA (1) | ZA201409095B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2725450T3 (es) | 2007-07-02 | 2019-09-24 | Etubics Corp | Métodos y composiciones para la producción de un vector adenoviral para su uso en vacunaciones múltiples |
| GB201214007D0 (en) | 2012-08-07 | 2012-09-19 | Scancell Ltd | Anti-tumour immune responses to modified self-epitopes |
| US9605276B2 (en) | 2012-08-24 | 2017-03-28 | Etubics Corporation | Replication defective adenovirus vector in vaccination |
| AU2015257929B2 (en) * | 2014-05-05 | 2020-06-25 | Novio Th B.V. | Method for the serological diagnosis of rheumatoid arthritis. |
| CN104360070B (zh) * | 2014-11-28 | 2017-02-22 | 山东新创生物科技有限公司 | 肽基精氨酸脱亚胺酶2在制备肿瘤临床血液诊断试剂中的应用 |
| CN113456812B (zh) | 2015-01-09 | 2024-08-20 | 埃图比克斯公司 | 用于联合免疫治疗的方法和组合物 |
| US11149087B2 (en) | 2015-04-20 | 2021-10-19 | Etubics Corporation | Methods and compositions for combination immunotherapy |
| KR20180006945A (ko) | 2015-05-13 | 2018-01-19 | 아게누스 인코포레이티드 | 암 치료 및 예방용 백신 |
| GB201512703D0 (en) | 2015-07-20 | 2015-08-26 | Scancell Ltd | Anti-tumour immune responses to modified self-epitopes |
| SG10202111399YA (en) | 2015-12-22 | 2021-11-29 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers |
| GB201522667D0 (en) * | 2015-12-22 | 2016-02-03 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers |
| WO2018046648A1 (en) * | 2016-09-08 | 2018-03-15 | Katholieke Universiteit Leuven | Citrullinated peptides for diagnosis or treatment of diabetes |
| KR102184377B1 (ko) * | 2018-02-19 | 2020-11-30 | 고려대학교 산학협력단 | 열충격단백질의 에피토프를 포함하는 백신 및 이의 용도 |
| JP2021522239A (ja) | 2018-04-26 | 2021-08-30 | アジェナス インコーポレイテッド | 熱ショックタンパク質結合ペプチド組成物およびその使用方法 |
| GB201815041D0 (en) | 2018-09-14 | 2018-10-31 | Scancell Ltd | Epitopes |
| GB202005779D0 (en) | 2020-04-21 | 2020-06-03 | Scancell Ltd | Anti-tumour immune responses |
| CN112194719A (zh) * | 2020-09-01 | 2021-01-08 | 中日友好医院(中日友好临床医学研究所) | Crt抗原和mage-a1抗原的制备及其应用 |
| GB202018395D0 (en) | 2020-11-23 | 2021-01-06 | Scancell Ltd | Immunotherapy |
| CN114404570B (zh) * | 2022-01-20 | 2023-05-30 | 中国药科大学 | 一种新型抗肿瘤转移多肽及其应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002051785A (ja) * | 2000-08-09 | 2002-02-19 | Hagiwara Yoshihide | 抗癌ヒトモノクローナル抗体ＣＬＮ−ＩｇＧによって認識される抗原エピトープのアミノ酸配列およびそれをコードするＤＮＡヌクレオチド配列 |
| WO2002034287A2 (en) * | 2000-10-27 | 2002-05-02 | Pharmexa A/S | Therapeutic vaccine formulations containing chitosan |
| US20030072737A1 (en) * | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| WO2003024191A2 (en) * | 2001-09-21 | 2003-03-27 | Raven Biotechnologies, Inc. | Antibodies that bind to cancer-associated antigen cytokeratin 8 and methods of use thereof |
| AU2003207459A1 (en) * | 2002-01-03 | 2003-07-24 | The Scripps Research Institute | Cancer-associated epitope |
| US20040013649A1 (en) * | 2002-05-10 | 2004-01-22 | Inex Pharmaceuticals Corporation | Cancer vaccines and methods of using the same |
| WO2004020462A1 (ja) | 2002-08-27 | 2004-03-11 | Fujii, Nobutaka | Ｃｘｃｒ４拮抗薬およびその用途 |
| JP2006518982A (ja) * | 2002-10-02 | 2006-08-24 | エフ．ホフマン−ラ ロシュ アーゲー | Ｍｈｃｉｉ結合ペプチド |
| US7670604B2 (en) * | 2002-12-13 | 2010-03-02 | Aurelium Biopharma, Inc. | Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease |
| DE10313819A1 (de) * | 2003-03-24 | 2004-10-07 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
| JP2007515924A (ja) * | 2003-12-15 | 2007-06-21 | アウレリウム バイオファーマ インク． | ビメンチン指向性診断法、および、多剤耐性を示す腫瘍性疾患の治療法 |
| WO2006120474A2 (en) * | 2005-05-13 | 2006-11-16 | Oxxon Therapeutics Ltd | Compositions for inducing an immune response against tumor antigens |
| DE102005029845B4 (de) * | 2005-06-27 | 2017-03-23 | Orgentec Diagnostika Gmbh | Verfahren zur Diagnose von rheumatischen Erkrankungen |
| CN1712964A (zh) * | 2005-07-18 | 2005-12-28 | 山东省医药生物技术研究中心 | 类风湿性关节炎特异性抗原性标志物及其应用 |
| US20070248628A1 (en) * | 2005-12-06 | 2007-10-25 | Keller Lorraine H | Immunogens in cancer stem cells |
| US8653039B2 (en) * | 2006-02-17 | 2014-02-18 | Robert J. Hickey | Peptide based inhibition of caPCNA interaction in cancer |
| US8404810B2 (en) * | 2006-02-17 | 2013-03-26 | Five Prime Therapeutics, Inc. | Compositions and methods of use for modulators of polypeptides and polynucleotides in treating breast cancer and melanoma |
| AU2007243442A1 (en) * | 2006-04-24 | 2007-11-08 | Shantha West, Inc. | AgRM2 antigen |
| EP1882697B1 (en) * | 2006-07-24 | 2010-04-21 | Institut Pasteur | Antibodies, antibody fragments and scFv binding to post-translationally modified neurotrophins |
| BRPI0814140A2 (pt) * | 2007-07-27 | 2017-03-28 | Immatics Biotechnologies Gmbh | composição de peptídeos associados a tumor e vacina anticâncer relacionada |
| EP2249865A4 (en) * | 2008-02-08 | 2012-04-04 | Scripps Research Inst | RUPTURE OF IMMUNOLOGICAL TOLERANCE WITH GENETICALLY CODED NON-NATURAL AMINO ACID |
| BR122013006960A2 (pt) * | 2009-03-30 | 2019-10-15 | Nestec S.A. | Peptídeo sintético que é imunologicamente reativo com um anticorpo de proteína anti-citrulinado, seu uso e seu método de identificação, bem como kit compreendendo o referido peptídeo |
| EP2569633B1 (en) * | 2010-05-14 | 2016-02-10 | The General Hospital Corporation | Compositions and methods of identifying tumor specific neoantigens |
| US20130303460A1 (en) | 2011-01-10 | 2013-11-14 | Biokine Therapeutics Ltd. | Peptides and compositions for the treatment of neuroectodermal derived tumors and retinoblastoma |
| EP2667888A4 (en) | 2011-01-28 | 2015-11-11 | Univ Oregon Health & Science | LIGMPHES OF RECOMBINANT T LYMPHOCYTES AND ANTIBODIES BINDING TO LYMPHOCYTES B FOR THE TREATMENT OF AUTOIMMUNE DISEASES |
| EP3412680B1 (en) | 2011-04-05 | 2020-11-04 | Curara AB | Novel peptides that bind to types of mhc class ii and their use in diagnosis and treatment |
| US20120295292A1 (en) * | 2011-05-19 | 2012-11-22 | University Of South Carolina | Detecting Protein Arginine Deiminase (PAD) Activity in Human Tissues and Sera |
| US20130274125A1 (en) * | 2012-04-16 | 2013-10-17 | Bio-Rad Laboratories Inc. | Multiplex immunoassay for rheumatoid arthritis and other autoimmune diseases |
| GB201214007D0 (en) | 2012-08-07 | 2012-09-19 | Scancell Ltd | Anti-tumour immune responses to modified self-epitopes |
-
2012
- 2012-08-07 GB GBGB1214007.5A patent/GB201214007D0/en not_active Ceased
-
2013
- 2013-08-07 DK DK13750368.6T patent/DK2883054T3/en active
- 2013-08-07 EP EP17194252.7A patent/EP3301447B1/en active Active
- 2013-08-07 KR KR1020157004947A patent/KR102203096B1/ko active IP Right Grant
- 2013-08-07 EP EP17194251.9A patent/EP3287787B1/en active Active
- 2013-08-07 PL PL17194252T patent/PL3301447T3/pl unknown
- 2013-08-07 PT PT171942527T patent/PT3301447T/pt unknown
- 2013-08-07 ES ES17194252T patent/ES2843777T3/es active Active
- 2013-08-07 CA CA2874515A patent/CA2874515A1/en active Pending
- 2013-08-07 JP JP2015525944A patent/JP6490581B2/ja active Active
- 2013-08-07 PL PL17194251T patent/PL3287787T3/pl unknown
- 2013-08-07 PT PT13750368T patent/PT2883054T/pt unknown
- 2013-08-07 WO PCT/GB2013/052109 patent/WO2014023957A2/en active Application Filing
- 2013-08-07 PT PT171942519T patent/PT3287787T/pt unknown
- 2013-08-07 DK DK17194251.9T patent/DK3287787T3/da active
- 2013-08-07 SG SG11201407804RA patent/SG11201407804RA/en unknown
- 2013-08-07 SG SG10201701001VA patent/SG10201701001VA/en unknown
- 2013-08-07 AU AU2013301341A patent/AU2013301341B2/en active Active
- 2013-08-07 ES ES13750368T patent/ES2681973T3/es active Active
- 2013-08-07 IN IN10629DEN2014 patent/IN2014DN10629A/en unknown
- 2013-08-07 BR BR112015002574A patent/BR112015002574A8/pt not_active Application Discontinuation
- 2013-08-07 EP EP13750368.6A patent/EP2883054B1/en active Active
- 2013-08-07 CN CN201380041701.3A patent/CN104823054B/zh active Active
- 2013-08-07 CN CN201611090520.1A patent/CN107043414A/zh active Pending
- 2013-08-07 ES ES17194251T patent/ES2833962T3/es active Active
- 2013-08-07 DK DK17194252.7T patent/DK3301447T3/da active
-
2014
- 2014-12-10 ZA ZA2014/09095A patent/ZA201409095B/en unknown
-
2015
- 2015-02-05 US US14/614,964 patent/US10233220B2/en active Active
- 2015-07-22 HK HK15106996.4A patent/HK1206427A1/xx unknown
-
2018
- 2018-06-13 US US16/007,944 patent/US20180346537A1/en not_active Abandoned
- 2018-06-26 JP JP2018120859A patent/JP2018197236A/ja active Pending
-
2020
- 2020-12-22 US US17/131,532 patent/US20210198334A1/en not_active Abandoned
-
2022
- 2022-08-01 US US17/878,533 patent/US20230192790A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN10629A (es) | ||
| MX2021013837A (es) | Enfoque de inmunoterapias de combinacion para el tratamiento del cancer. | |
| MX2019010601A (es) | Terapia de combinacion para tratar cancer. | |
| GEP20237538B (en) | Pd-1-binding molecules and methods of use thereof | |
| MX2017005258A (es) | Terapia combinada para tratamiento de enfermedad. | |
| MX2021013830A (es) | Inhibidores de ezh2 para tratar linfomas. | |
| EA201890961A1 (ru) | Комбинированная терапия для лечения злокачественных новообразований | |
| MX2018008052A (es) | Inhibidores de desmetilasa especifica de lisina 1 (lsd1). | |
| EA201992251A1 (ru) | Противораковые вакцины и способы лечения с их применением | |
| PH12015500525A1 (en) | Formulations of enzalutamide | |
| MX2015004771A (es) | Metodos para tratar cancer. | |
| PH12015502042A1 (en) | Use of linagliptin in cardio-and renoprotective antidiabetic therapy | |
| MX369691B (es) | Inhibidores de glutaminasa y métodos de empleo. | |
| EP2844736A4 (en) | Modified bacteria and uses thereof for the treatment of carcinomas or tumors | |
| EA201400625A1 (ru) | Антитела против pd-l1 и их применение | |
| GB201209613D0 (en) | New compounds | |
| TW201611843A (en) | Methods of treatment with arginine deiminase | |
| MY180613A (en) | Combination therapies for melanoma comprising administering cobimetinib and vemurafinib | |
| GEP20217317B (en) | Combination therapy for the treatment of cancer | |
| MX2015014046A (es) | Combinaciones de farmacos para tratar cancer. | |
| EA201590703A1 (ru) | Ингибиторы mek при лечении вирусных заболеваний | |
| MX356755B (es) | Compuestos de tipo fumagilol y metodos para su elaboración y uso. | |
| MX344590B (es) | Inhibidores de f1f0-atpasas de tipo pirazolilguanidina y sus usos terapéuticos. | |
| BR112015006705A8 (pt) | antiandrogênios para o tratamento de câncer de próstata resistente à castração não metastático e usos destes | |
| MX2013006398A (es) | Inhibidores de f1f0-atpasas de tipo piridonilguanidina y usos terapeúticos. |